NCT00699816已完成3 期
Randomized, Open-label, Multi-center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of 'Green Cross CELL Immuncell-LC Group' and 'Non-treatment Group' in Patient Undergone Curative Resection(PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 230
- 试验地点
- 10
- 主要终点
- Recurrence Free Survival(RFS)
研究概览
简要总结
To prove that the efficacy and safety of 'Green Cross CELL* Immuncell-LC group' is superior to 'non-treatment group(Control group)' in patient undergone curative resection(PEIT, RFA or operation) for hepatocellular carcinoma in Korea
详细描述
Multicenter, randomized, open-labeled phase 3 clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prior to the test, patient is fully explained about the purpose/ contents and characteristics of the testing medication, and the patient him(her)self, the guardian or the legal representative signed on written consent.
- •The patient is more than 20 and less than 80 years old
- •The patient is diagnosed as hepatocellular carcinoma by pathological/ radiological test and he (she) is in the stage of I or II. (refer to the attached file 10). Hepatocellular carcinoma should be shown by radiological test; on dynamic CT, dynamic MRI or on angiography.
- •Child-Pugh Score should be less than 6 (refer to the attached file 7)
- •No matter how the patient has been treated before, his (her) tumor should be totally removed by curative resection (PEIT, RFA or operation) in 12 weeks. (based on the agreement date for written consent) The tumor's removal should be perfectly confirmed by pathological or radiological test with the mentioned method in 3) at least 4 weeks later.
- •ECOG Performance status (ECOG-PS) is less than 1 or equal to (refer to the exhibit 8)
- •Patient's remaining life-time should be expected at least more than 3 months.
- •Patient should meet below conditions by blood test, kidney and liver function test
- •: Re-evaluation is possible during screening
- •Leukocyte count is bigger than (3 multiply 109/L)
- •Absolute Neutrophil Count (ANC) is bigger than or equal to 1,000/µL
- •Hemoglobin is bigger than or equal to 8.5 g/dL
- •Thrombocyte count is bigger than (5 multiply 1010/L)
- •BUN and serum Creatinine is less than or equal to 1.5 multiply normal upper-limit
- •No more disease abdominal extrahepatic transfer is confirmed by abdominal CT/ MRI
排除标准
- •Hepatocellular carcinoma has been transferred by pathological/ radiological test (Stage III or Stage IV, refer to the exhibit 10)
- •The carcinoma has been invaded to main portal vein or major branch hepatic vein
- •Child-Pugh score is over 6
- •Patient has serious problem with pulmonary function by sub- investigator's opinion
- •Patient who has disease history of immune deficiency (which can be worse by immunotherapy) or auto-immune disease (ex. arthritis rheumatism, Burger's disease, multiple sclerosis and adolescent-occurred insulin dependent diabetes)
- •Diagnosed as an immune deficiency patient
- •Patient who has disease history of malignant tumor within 5 years before this clinical trial. (except for skin cancer, local prostate cancer or carcinoma in situ of the uterine cervix
- •Patient who had anti-cancer medication before the clinical trial
- •Patient who has serious disease in other organs after tumor resection.
- •Patient has serious allergic-history by sub- investigator's opinion
- •Patient has serious mental disease by sub- investigator's opinion
- •Pregnant women, nursing mother or having intention of being pregnant during the clinical test
- •Patient who participated in other clinical trial within 4 weeks before this clinical trial
- •Patient who is incongruent to this clinical trial by sub- investigator's opinion.
结局指标
主要结局
Recurrence Free Survival(RFS)
时间窗: Every 3months from the baseline for 24 months and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)
RFS was measured from the date of randomization to the first recurrence or to death from any cause.
Recurrence Free Survival(RFS) Rate
时间窗: Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)
RFS rate was measured from the date of randomization to the first recurrence or to death from any cause.
次要结局
- Cancer-specific Survivals(Every 3 months from baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit))
- Overall Survival(OS)(Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit))
- Overall Survival(OS) Rate(Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit))
- Cancer-specific Survival Rate(Every 3 months from baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit))
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of "Immuncell-LC" in TACE TherapyCarcinoma, HepatocellularNCT02856815GC Cell Corporation76
已完成
3 期
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyAdvanced Upper Gastrointestinal Tract AdenocarcinomaNCT05568095Arcus Biosciences, Inc.1,040
已完成
3 期
Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of KoreaGlioblastomaNCT00807027GC Cell Corporation180
已完成
3 期
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney TransplantsKidney Transplant RejectionNCT03363945Medeor Therapeutics, Inc.30
已完成
3 期
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised SubjectsHSV InfectionNCT03073967AiCuris Anti-infective Cures AG158